Polycystic ovarian syndrome (PCOS) is the accumulation of underdeveloped follicles in the ovaries due to anovulation. It is is characterized by menstrual abnormalities and clinical or biochemical features of hyperandrogenism.
It results mainly from abnormal steroidogenesis that may be caused by insulin resistance leading to hyperinsulinemia.
There is increased sensitivity to androgens and the majority of women have elevated androgen levels.
Sedentary behaviour remains extremely prevalent among overweight or obese women with polycystic ovary syndrome (PCOS), with a recent study reporting that only one in two women meets physical activity (PA) levels recommended for weight loss.
Middle-aged women with polycystic ovary syndrome (PCOS) exhibit only a moderately unfavourable cardiometabolic profile despite having an increased body mass index (BMI) and waist circumference, as reported in a study.
In the management of women with polycystic ovary syndrome (PCOS) and obesity, rosiglitazone monotherapy or in combination with low-dose metformin plus lifestyle modification should be recommended to those with abnormal lipid profiles, according to the results of a trial.